Shares of Venus Remedies surged over 11% in Wednesday’s trade, climbing to ₹347.65 on the NSE, after the company announced that its novel antibiotic formulation VRP-034 has received Qualified Infectious Disease Product (QIDP) designation from the United States Food and Drug Administration (US FDA). The stock hit a day high of ₹347, up from its previous close of ₹312.65, adding ₹35 in market value.
The QIDP status, granted under the GAIN (Generating Antibiotic Incentives Now) Act, offers Venus Remedies a significant regulatory edge—including fast-track review, priority regulatory clearance, and five additional years of market exclusivity once the drug is approved.
About VRP-034: VRP-034 is an innovative supramolecular cationic formulation of polymyxin B sulfate, targeted at treating bloodstream infections caused by polymyxin B-susceptible strains in adult patients. It addresses one of the key limitations of existing treatments—nephrotoxicity—without compromising therapeutic potency.
Key preclinical findings include:
- Up to 70% reduction in nephrotoxicity compared to traditional polymyxin B therapies
- High efficacy against drug-resistant pathogens in both lab and animal studies
- Strong safety profile validated through organ-on-a-chip and real-time biomarker technology
Innovation and R&D: The drug was developed by the Venus Medicine Research Centre (VMRC), leveraging the company’s proprietary Renal Guard technology. Kidney-on-a-chip platforms were instrumental in monitoring renal damage biomarkers in real time, making the safety evaluation more precise.
CEO Commentary: Saransh Chaudhary, CEO of VMRC, said, “Receiving QIDP designation is a pivotal milestone in our fight against antimicrobial resistance and validates the strength of our scientific approach.”
As of 10:09 AM, the company’s stock had jumped by 11.19% with a market capitalization of ₹4.61 billion and a P/E ratio of 13.21.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.